Join to view full profile
800 Rose Street, CC454University of Kentucky Medical CenterLexington, KY 40536
Phone+1 859-323-6522
Fax+1 859-257-7715
Dr. Anthony is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lowell Anthony is an oncology specialist based in Lexington, KY, with a focus on gastrointestinal cancer and hematologic oncology. He completed his medical education and training at Vanderbilt University Medical Center, where he gained significant experience in internal medicine, hematology, and medical oncology. Dr. Anthony currently serves as the Chief of the Division of Medical Oncology at the University of Kentucky College of Medicine. His clinical and research expertise includes carcinoid tumors, lung cancer, neuroendocrine tumors, and small cell lung cancer, with a notable publication record on these topics. He has been involved as a principal investigator in several clinical trials aimed at advancing treatments for neuroendocrine tumors. His contributions have been recognized with several awards, including being named to America’s Top Doctors and receiving CMS Meaningful Use certifications.
Education & Training
Vanderbilt University Medical CenterFellowship, Clinical Pharmacology, 1985 - 1987- Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
- Vanderbilt University Medical CenterResidency, Internal Medicine, 1979 - 1982
Vanderbilt University School of MedicineClass of 1979
Certifications & Licensure
KY State Medical License 2011 - 2027
TN State Medical License 1981 - 2016
LA State Medical License 1996 - 2011
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
- America's Top Doctors Castle Connolly, 2009-2014
Clinical Trials
- A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Start of enrollment: 2009 Jun 04
- A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
- Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Start of enrollment: 2017 Feb 14
Publications & Presentations
PubMed
- Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).Aman Chauhan, Heidi L Weiss, Charles Kunos, Rani Jayswal, Bhavana Konda
Clinical Cancer Research. 2026-10-15 - A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.Aman Chauhan, Elise C Kohn, S Percy Ivy, Jill M Kolesar, Rakhi Modak
Frontiers in Oncology. 2026-01-01 - Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians.Zhonglin Hao, John Villano, Susanne M Arnold, Lowell Anthony
Therapeutic Advances in Medical Oncology. 2026-01-01
Press Mentions
Dedicated Neuroendocrine Tumors Program Launched at Sylvester Comprehensive Cancer CenterMarch 16th, 2023- Sylvester Recruits Aman Chauhan, M.D., to Lead Neuroendocrine Tumor ProgramMarch 16th, 2023
- UK Markey Cancer Foundation Funds First Professorship in Neuroendocrine Tumor ResearchMarch 29th, 2022
Grant Support
- Safety And Efficacy Of PTK787/ZK222584 In Patients With Neuroendocrine CancerNational Center For Research Resources2006
- Study To Evaluate The Effect Of Age And Renal Function Of OctreoscanNational Center For Research Resources2005–2006
- Study To Evaluate The Effect Of Age And Renal FunctionNational Center For Research Resources2004
- Study Comparing Venofer Intravenously To NO Iron TxNational Center For Research Resources2004
- Clinical Trial With Thymitaq Administered To PatientsNational Center For Research Resources2004
Professional Memberships
- Member
- Member
- Member
- North American Neuroendocrine Tumor SocietyMember
- Multinational Association of Supportive Care in CancerMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
